生长抑素受体靶向PET/CT对神经内分泌肿瘤患者管理的影响:系统综述与荟萃分析
该系统综述与荟萃分析检索PubMed数据库,纳入14项研究共1561例神经内分泌肿瘤患者,评估生长抑素受体PET/CT后管理变化。SSTR PET/CT后44%(范围16%-71%)患者管理发生改变;在4项于111In-Octreotide扫描后行SSTR PET/CT的研究中,该比例为39%(范围16%-71%)。14项研究中7项区分了跨模态与模态内变化,多数为跨模态(77%;模态内23%)。
要点
- SSTR PET/CT后44%(范围16%-71%)的神经内分泌肿瘤患者管理发生改变。
- 在111In-Octreotide扫描后行SSTR PET/CT的4项研究中,39%(范围16%-71%)患者管理改变。
- 7项研究区分变化类型,跨模态变化占77%,模态内变化占23%。
核心结论
- 超过三分之一的神经内分泌肿瘤患者在接受SSTR PET/CT后管理发生改变,即使在111In-Octreotide扫描后行SSTR PET/CT也是如此。
- 跨模态变化约为模态内变化的3倍,凸显了SSTR PET/CT的临床影响。
研究设计与样本
- 系统综述与荟萃分析,检索美国国家生物技术信息中心PubMed在线数据库,关键词为「management」AND「PET」AND「neuroendocrine」。
- 190项研究中14项符合纳入标准:原创研究、队列研究、患者数10例或以上、报告SSTR PET/CT后管理变化。
- 共纳入1561例患者,管理变化采用随机效应模型汇总。
主要发现
- 总体而言,SSTR PET/CT后44%(范围16%-71%)的神经内分泌肿瘤患者管理发生改变。
- 14项研究中有4项在111In-Octreotide扫描后行SSTR PET/CT,该亚组中SSTR PET/CT提供的额外信息使39%(范围16%-71%)的患者管理发生改变。
- 14项研究中有7项区分了跨模态与模态内变化,多数变化为跨模态(77%;模态内23%)。
关键数值与推荐
- 纳入标准:原创研究、队列研究、患者数10例或以上、报告SSTR PET/CT后管理变化。
- 总体管理变化率44%(范围16%-71%)。
- 111In-Octreotide扫描后行SSTR PET/CT亚组的管理变化率39%(范围16%-71%)。
- 区分变化类型的7项研究中,跨模态变化77%,模态内变化23%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatostatin receptor (SSTR) imaging is widely used for guiding the management of neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the U.S. Food and Drug Administration has triggered widespread clinical interest in SSTR PET/CT throughout the United States. Here, we performed a systematic review and meta-analysis to evaluate the impact of SSTR PET/CT on the management of patients with NETs. Methods: A comprehensive literature search was performed using The National Center for Biotechnology Information PubMed online database, applying the following key words: "management" AND "PET" AND "neuroendocrine". Fourteen of 190 studies were deemed suitable based on the following inclusion criteria: original research, cohort study, number of patients 10 or more, and reported change in management after SSTR PET/CT. Change in management across studies was determined by a random-effects model. Results: A total of 1,561 patients were included. Overall, change in management occurred in 44% (range, 16%-71%) of NET patients after SSTR PET/CT. In 4 of 14 studies, SSTR PET/CT was performed after an 111In-Octreotide scan. In this subgroup, additional information by SSTR PET/CT led to a change in management in 39% (range, 16%-71%) of patients. Seven of 14 studies differentiated between inter- and intramodality changes, with most changes being intermodality (77%; intramodality, 23%). Conclusion: The management was changed in more than one third of patients undergoing SSTR PET/CT even when performed after an 111In-Octreotide scan. Intermodality changes were 3 times more likely than intramodality changes, underlining the clinical impact of SSTR PET/CT.
引用
- Barrio M, Czernin J, Fanti S, et al. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. J Nucl Med. 2017. PMID: 28082438. doi:10.2967/jnumed.116.185587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。